MONICA SAMUEL AVILA GRINBERG
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
conferenceObject American Population Derived Donor Score System Assessment in a Brazilian Heart Transplantation Cohort(2017) ESCOSSIA, L. L.; BONATTO, M. G.; TONIN, M. H.; MANGINI, S.; MARCONDES-BRAGA, F.; BACAL, F.; AVILA, M. S.; WOSNIAK, I.; SEGURO, L.; DUTRA, A. C.; PAULO, A. R. de; MELO, J. L.; BARONE, F.- Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients(2017) RIGAUD, Vagner Oliveira-Carvalho; FERREIRA, Ludmila R. P.; AYUB-FERREIRA, Silvia M.; AVILA, Monica S.; BRANDAO, Sara M. G.; CRUZ, Fatima D.; SANTOS, Marilia H. H.; CRUZ, Cecilia B. B. V.; ALVES, Marco S. L.; ISSA, Victor S.; GUIMARAES, Guilherme V.; CUNHA-NETO, Edecio; BOCCHI, Edimar A.Cardiotoxicity is associated with the chronic use of doxorubicin leading to cardiomyopathy and heart failure. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable prognostic tool. The aim of the study was to evaluate circulating levels of miRNAs in breast cancer patients receiving doxorubicin treatment and to correlate with cardiac function. This is an ancillary study from ""Carvedilol Effect on Chemotherapy-induced Cardiotoxicity"" (CECCY trial), which included 56 female patients (49.9 +/- 3.3 years of age) from the placebo arm. Enrolled patients were treated with doxorubicin followed by taxanes. cTnI, LVEF, and miRNAs were measured periodically. Circulating levels of miR-1,-133b,-146a, and -423-5p increased during the treatment whereas miR-208a and -208b were undetectable. cTnI increased from 6.6 +/- 0.3 to 46.7 +/- 5.5 pg/mL (p<0.001), while overall LVEF tended to decrease from 65.3 +/- 0.5 to 63.8 +/- 0.9 (p=0.053) over 12 months. Ten patients (17.9%) developed cardiotoxicity showing a decrease in LVEF from 67.2 +/- 1.0 to 58.8 +/- 2.7 (p=0.005). miR-1 was associated with changes in LVEF (r=-0.531, p<0.001). In a ROC curve analysis miR-1 showed an AUC greater than cTnI to discriminate between patients who did and did not develop cardiotoxicity (AUC = 0.851 and 0.544, p = 0.0016). Our data suggest that circulating miR-1 might be a potential new biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
conferenceObject Long-Distance Heart Procurement and One-Year Survival: A Retrospective Cohort Study(2017) BRAGA, G. A.; MARCONDES-BRAGA, F. G.; XAVIER JUNIOR, J. L.; SILVA, M. da; MANGINI, S.; AVILA, M. S.; SOUZA, G. C. de; SEGURO, L. B.; CAMPOS, I. W.; BONATTO, M.; HOFFMANN, M.; ESCOSSIA, L.; SANTOS, R. N.; GAIOTTO, F. A.; BACAL, F.conferenceObject One Year Survival After Heart Transplantation: Chagasic x Non-Chagasic Patients(2017) XAVIER, J. L.; MARCONDES-BRAGA, F. G.; BRAGA, G. A.; SILVA, M.; SOUZA, G. C.; MANGINI, S.; AVILA, M. S.; SEGURO, L. B.; TONIN, M. D.; ESCOSSIA, L. L. Da; BONATTO, M. G.; MELO, J. L. De; GAIOTTO, F. A.; BACAL, F.conferenceObject Osteoporosis in Heart Transplant: association with pre -transplant hospitalization time(2017) SEGURO, L. F. B. C.; SEGURO, L. P. C.; MARCONDES-BRAGA, F. G.; CAPARBO, V. P.; TAKAYAMA, L.; MANGINI, S.; AVILA, M. S.; WOZNIAK, I.; GAIOTTO, F. A.; PEREIRA, R. M.; BACAL, F.